ArticleRSC advances2026

Development of a multi-targeted sulfonyl-bridged bisselenadiazole derivative as a potent EGFR/PI3K/AKT/mTOR modulator in lung adenocarcinoma.

Wesam Abd El-Fattah et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.